Cascade Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Cascade Pharmaceuticals is a clinical-stage biotech company specializing in metabolic and anti-inflammatory drugs targeting nuclear receptors and G protein–coupled receptors (GPCRs).
Our lead asset Linafexor (CS0159), a small molecule farnesoid X receptor (FXR) agonist, differentiated with short half and high potency by design, mitigating liabilities associated with the MOA. In our clinical trial completed recently, compared with semaglutide alone, combo use significantly improved the effect of body weight loss while preserving the lean body mass.
We also have a potential best in class THR-beta program with better selectivity over THR-alpha, and more potency than MGL-3196. More importantly, we have demonstrated >10X synergy with GLP1R peptide or small molecule agonists in animal obesity models.
In addition, GLP-1, GCG, and GIP represent attractive targets for managing obesity and metabolic disorders. We have discovered lead small molecule GIPR/GCGR agonist.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}